Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of buagafuran in preparation of medicine for preventing and/or treating related diseases of amphetamine-type drug addiction

A kind of technology of amphetamines and related diseases, applied in the field of medicine, can solve problems such as no drugs yet

Active Publication Date: 2020-11-17
BEIJING UNION PHARMA FACTORY
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the detoxification drugs approved for marketing at home and abroad, such as methadone and naloxone, are all substitutes for opioid drugs, and there is no drug that can effectively treat the addiction caused by amphetamine-type stimulants.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of buagafuran in preparation of medicine for preventing and/or treating related diseases of amphetamine-type drug addiction
  • Application of buagafuran in preparation of medicine for preventing and/or treating related diseases of amphetamine-type drug addiction
  • Application of buagafuran in preparation of medicine for preventing and/or treating related diseases of amphetamine-type drug addiction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1: Effect of Bugfuran itself on the excitability of mice.

[0042] First arrange the mice to acclimatize in the behavior box for 3 days, 4 hours a day. Test day four. During the test, arrange the mice to move freely in the behavior box for 30 minutes, then intraperitoneally inject Bugfuran, and then put the animals back into the behavior box to record for 1 hour. The specific dosage is as follows:

[0043] 1) Blank group (10% Tween 80 normal saline solution, 2.5mL / kg, intraperitoneal injection) n=12

[0044] 2) AF1 (bugfuran dissolved in normal saline solution containing 10% Tween 80, dose 1mg / kg, intraperitoneal injection) n=5

[0045] 3) AF10 (bugfuran dissolved in normal saline solution containing 10% Tween 80, dose 10mg / kg, intraperitoneal injection) n=5

[0046] 4) AF50 (bugfuran dissolved in normal saline solution containing 10% Tween 80, dose 50mg / kg, intraperitoneal injection) n=5

[0047] The effect of Bugfuran on the excitability of mice was evalu...

Embodiment 2

[0048] Embodiment 2: CPP training-environmental adaptability and the impact of medicine on animal body weight

[0049] CPP training was carried out on the mice. As mentioned above, the CPP training was carried out for 4 days, twice a day, 20 minutes each time, with an interval of 4 hours in between. In the first experiment, normal saline was administered and placed in the saline compartment, and in the second experiment, drugs (bugfuran, amphetamine or combined administration) were administered and placed in the dosing compartment. The specific dosage is as follows:

[0050] 1) Blank group (0.9% normal saline, 2.5mL / kg, intraperitoneal injection) n=13

[0051] 2) AF5 (bugfuran dissolved in normal saline solution containing 10% Tween 80, dose 5mg / kg, intraperitoneal injection) n=6

[0052] 3) AF20 (bugfuran dissolved in normal saline solution containing 10% Tween 80, dose 20mg / kg, intraperitoneal injection) n=9

[0053] 4) AF5+AMPH (5mg / kg Bugfuran+1mg / kg Amphetamine, intrap...

Embodiment 3

[0057] Example 3: Effect of Bugfuran on CPP Formation and Effect on Amphetamine-Induced CPP Formation

[0058] Bugfuran was given to mice alone to evaluate the effect of Bugfuran itself on the formation of CPP; mice were given a mixed solution of Bugfuran and amphetamine to evaluate the effect of Bugfuran on the formation of CPP induced by amphetamine. The CPP formation test was performed after completing the CPP training. On the day of the test, the mice were placed in the shuttle box to move freely, and the time of the animals staying in each compartment was counted for 20 minutes. The specific dosage is as follows:

[0059] 1) Blank group (0.9% normal saline, 2.5mL / kg, intraperitoneal injection, n=13)

[0060] 2) AF5 (bugfuran dissolved in normal saline solution containing 10% Tween 80, dose 5mg / kg, intraperitoneal injection) n=6

[0061] 3) AF20 (bugfuran dissolved in normal saline solution containing 10% Tween 80, dose 20mg / kg, intraperitoneal injection) n=9

[0062] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of buagafuran for the prevention and / or treatment of addiction to amphetamine drugs. The amphetamine-type drugs comprise but are not limited to amphetamine, methamphetamine, fenfluramine, phentermine, amphetamine sulfate, methylene dioxymetham-phetamine, Tenamfetamine, dimethyl phenylethylamine or one or more of pharmaceutically acceptable salts of the above-mentioned substances.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of Bugfuran in the preparation of medicines for preventing and / or treating diseases related to amphetamine drug addiction. Background technique [0002] Amphetamine-type stimulants are currently the most common illegal drugs of abuse, which can be divided into three categories: (1) traditional amphetamine-type stimulants, the main representative drugs are amphetamine and methamphetamine; Stimulant, addictive. Methamphetamine hydrochloride, or "ice", has a longer duration of drug effect than opioids such as morphine and heroin, and is more harmful. (2) Slimming amphetamine-type stimulants, the main representative drugs are fenfluramine, phentermine and amphetamine sulfate. (3) Hallucinogenic amphetamine-type stimulants, the main representative drugs are methamphetamine (MDMA), methamphetamine (MDA), dimethylphenethylamine (MDEA), etc., and the so-called "ecsta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61K31/343A61K31/138A61K31/4525A61K31/135A61K31/495A61K31/5513A61K31/4515A61P25/30A61P25/36A61P25/20A61P25/24
CPCA61K31/352A61K31/343A61K31/138A61K31/4525A61K31/135A61K31/495A61K31/5513A61K31/4515A61P25/30A61P25/36A61P25/20A61P25/24A61K2300/00
Inventor 汪小涧董梁
Owner BEIJING UNION PHARMA FACTORY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com